Table 2 Selected studies on CAR-T-based treatment for T-ALL from 2022 ASH annual meeting

Authors (references)

Zhang et al. [7]

Zhang et al. [8]

Tan et al. [9]

Wong et al. [10]

Study agents

NS7CAR-T

CD7 UCAR-T (RD13-01)

CD7 CAR-T

PCART7-CD3 PEBL

Analysis

I/II

I

II

N/A

NCT No

NCT04572308, NCT04916860

NCT04620655

NCT04689659

N/A

Study period

2020–2022

2020–2022

N/A

N/A

Age range, years

2–47

2–27

2–43

N/A

No. of patients

53 (34 T-ALL; 18 T/LBL)

10 (7 T-ALL; 3 T/LBL)

20

N/A

MRD analysis used to assign risk/postremission therapy

Yes

Yes

No

N/A

Outcome measure

OS, EFS

CR

ORR, 1-year PFS, 1-year OS

N/A

Survival outcome

18-month OS: 75.0%; 18-month EFS: 53.1%

CR: 80%

ORR: 90% at 3 months post-infusion; 1-year PFS: 62.3%; 1-year OS: 60.0%

N/A

Summary

NS7CAR therapy is safe and effective in R/R T-ALL/LBL patients with heavy pretreatment

RD13-01 product was safe and dose-dependently effective

Phase 2 trial of donor-derived CD7 CAR T cell therapy showed similar encouraging activity in treating R/R T-ALL with phase I trial

PCART7-CD3 PEBL showed minimized fratricide and a reduced risk of GvHD in a xenograft model. Clinical trials are needed to verify the feasibility in humans